FDA Authorizes First COVID-19 Treatment Pill, Pfizer’s Paxlovin Drug

What’s next?

The FDA has granted “Emergency Use Authorization” to Pfizer’s Paxlovid – nirmatrelvir and ritonavir tablets.

Join Our Telegram channel here:

The agency released a statement explaining that ritonavir tablets are fit “for the treatment of mild-to-moderate coronavirus disease in adults and children 12 years of age or older weighing at least 40 kilograms or about 88 pounds.”

According to them, this drug is fit for people “who are at high risk for progression to severe COVID-19, including hospitalization or death.”

FDA’s Director of the Center of Drug Evaluation and Research, Dr. Patrizia Cavazzoni explained:

“Today’s authorization introduces the first treatment for COVID-19 that is in the form of a pill that is taken orally — a major step forward in the fight against this global pandemic.

This authorization provides a new tool to combat COVID-19 at a crucial time in the pandemic as new variants emerge and promises to make antiviral treatment more accessible to patients who are at high risk for progression to severe COVID-19.”

Fox News says that the recommended “treatment involves taking two tablets of nirmatrelvir and one tablet of ritonavir — together orally twice daily for five days, for a total of three 30 tablets.”

Of course, Paxlovid is “not authorized for use for longer than five consecutive days.”

The FDA explained that Paxlovid is not a substitute for COVID jabs and is “not authorized for the pre-exposure or post-exposure prevention of COVID-19, or for initiation of treatment in those requiring hospitalization due to severe or critical COVID-19.”

There’s more. The drug shouldn’t be used by “patients with severe kidney or severe liver impairment,” is a “prescription only” medication. They say this medication works best when used immediately after receiving a positive COVID test.

VAERS has reported serious side effects caused by Pfizer jabs, but the company says that in “randomized, double-blind, placebo-controlled clinical trial, Paxlovid significantly reduced the proportion of people with COVID-19 related hospitalization or death from any cause by 88% compared to placebo among patients treated within five days of symptom onset and who did not receive COVID-19 therapeutic monoclonal antibody treatment.”

In the final words of the report, the FDA said that Paxlovid and other COVID medication made by Pfizer will undergo further evaluation.

Join Our Telegram channel here:

Source: Resist The Mainstream


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker